III disease). Neoadjuvant chemoradiotherapy (nCRT) has been shown to significantly reduce the local recurrence rate and has been associated with an increase in the overall survival rate. 2 Despite this, a large percentage of patients in the US still undergo a total proctectomy (abdominoperineal resection) with permanent end colostomy. In contrast, few patients undergo rectal-preserving treatments, such as local excision, or achieve complete tumor disappearance and thereby avoid any surgery whatsoever. 3, 4 The traditional North American paradigm for delivery of neoadjuvant therapy in rectal cancer consists of 45 to 50.4 Gray (Gy) delivered in 25 to 28 fractions, with sensitizing continuous fluorouracil infusion or capecitabine administered throughout the radiation course. Patients then undergo surgical resection approximately 6 to 8 weeks after finishing nCRT. 5, 6 This recommendation is based primarily on the Lyon R90-01 trial, which found improved clinical tumor response and pathologic downstaging in patients undergoing surgery 6 to 8 weeks after radiation therapy compared with those with a 2-week interval. 7 As a result of neoadjuvant therapy, many patients experience significant tumor downstaging, and some are found to have a pathologic complete response (pCR) on histologic examination of the resected specimen. 8, 9 There is a growing body of data that suggests that pCR is significantly associated with a reduction in both local and systemic recurrence and superior overall survival compared with that in patients with partial or no response. 10 Although pCR may potentially be a marker for favorable tumor biology, it is still imperative in clinical practice to attempt to maximize our chances of attaining pCR. This is especially true if a nonoperative or observational approach is to be considered.
So there is great clinical interest in identifying factors that may increase tumor regression and enhance the pCR rate. This has prompted some researchers to examine the relationship between the length of time between nCRT completion and surgery (nCRTesurgery interval) and subsequent tumor response. These studies suggested a potential association between a longer nCRTesurgery interval and an increased rate of pCR. 11 However, this work has been primarily from single institutions with small sample sizes (between 33 and 397 patients). Consequently, these studies lack sufficient power to adjust for the confounding impact of different radiotherapy dosages and variations in time to surgery after neoadjuvant therapy. The aim of this study was to examine the relationship between an increased nCRTesurgery interval compared with the current standard of care and pCR in a large, nationally representative cohort of rectal cancer patients who underwent neoadjuvant therapy before definitive surgical resection.
METHODS

Study population
Data for this study were retrieved retrospectively from the National Cancer Data Base (NCDB). This hospital-based cancer registry is sponsored by a joint program between the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The database collects information on all types of cancer from more than 1,500 hospitals with Commission-accredited cancer programs in the United States and Puerto Rico. Available information includes patient demographics, treatment regiments, tumor histology, and oncologic staging, as well as other patient characteristics. 12 Participating NCDB institutions report information based in the Facility Oncology Data Standards manual. 13 A total of 321,768 rectal cancer cases were identified in the NCDB Participant User File report. The analysis was limited to cases of adenocarcinoma, mucinous adenocarcinoma, and signet ring cell carcinoma diagnosed between 2006 and 2011. The sample was further restricted to patients with clinical stage II and III rectal cancer who underwent chemoradiotherapy before surgery and who had a documented surgical resection. Patients with incomplete information about time from diagnosis to surgery and radiation as well as pathologic T and N status were excluded, for a total sample size of 17,255. Figure 1 shows this inclusion process.
Measurement of neoadjuvant chemoradiotherapye surgery interval time
The database does not contain an explicit variable for nCRTesurgery interval time, but does contain information on number of days between the date of initial diagnosis and the date of the most definitive surgical procedure (A), number of days between the date of diagnosis and the date of radiation therapy initiation at any facility (B), and number of days of radiation therapy treatment (C). The nCRTesurgery interval time was calculated using the following formula: nCRTesurgery interval time ¼ A e B e C. A priori, the nCRTesurgery interval time was categorized as <6 weeks, 6 to 8 weeks, and >8 weeks, based on current clinical practice of a 6-to Abbreviations and Acronyms NCDB ¼ National Cancer Data Base nCRT ¼ neoadjuvant chemoradiotherapy OR ¼ odds ratio pCR ¼ pathologic complete response 8-week interval. Patients with a short interval of <6 weeks were categorized separately in order to avoid artificially biasing the estimate for patients with an interval of >8 weeks. In a sensitivity analysis, patients in the <6 week group were excluded from the sample and the main analysis was repeated. Because these results were consistent with those from the first analysis, we present the results of the analysis that includes this group because they represented 25% of the cohort.
Measurement of pathologic complete response
The primary endpoint was pCR (ypT0N0). The NCDB does not contain an explicit variable for pCR, but contains individual variables for pathologically determined tumor size and/or extension 14 and pathologically determined absence, presence, or extent of regional lymph node metastasis (pN). Patients with pT0 and pN0 were defined as having a pCR and all others were defined as not having a pCR.
Main analyses
Chi-square tests and ANOVA, as appropriate to the data, were used to compare covariate distributions between the 2 outcomes groups and the 3 nCRTesurgery interval time groups. A priori, patient, hospital, and treatment characteristics that achieved a p value < 0.20 in bivariate analyses were included in multivariable analyses. These characteristics included age, sex, race, insurance status, education, income, metro/urban residence, facility location, facility type, facility volume, clinical stage, histology type, radiation dose, treatment regimen, and tumor size. Logistic regression models were used to assess the association between nCRTesurgery interval time and the odds of having pCR. Interaction terms were added to the multivariable logistic model (nCRTesurgery interval time*dose and nCRTesurgery interval time*treatment regimen) to assess for heterogeneity of the effect of the nCRTesurgery interval time for different levels of radiation dosage and treatment regimen. The p values for both of the interaction terms were not statistically significant and therefore were left out of the final model. All multivariable models used the propensity score method in order to adjust for selection effects of the observational dataset. The propensity score is the probability of being in an interval group given the covariates in the model. It was estimated using a multivariable multinomial logistic regression model and included as a covariate in all models.
In an attempt to identify a more specific nCRTe surgery interval time associated with the highest odds of pCR, a separate analysis was conducted in which patients were categorized into weekly interval groups (<6 weeks, 6 to 8 weeks, 8 to 9 weeks, 9 to 10 weeks, etc). A separate multivariable logistic regression model was used to assess the relationship between this new interval variable and odds of pCR.
Secondary analyses A series of analyses were conducted to determine if there was an association between nCRTesurgery interval time and several secondary outcomes. Multivariable logistic regression models were used to estimate the effect of nCRTesurgery interval time on 30-day mortality, 30-day unplanned readmission, and tumor downstaging (pT< cT or pN < cN vs no downstaging). An ordinal logistic regression model was used to assess the association between tumor regression grade (pCR, moderate response, minimal response, poor response) and nCRTesurgery interval time. All analyses were performed using SAS software, version 9.3 (SAS Institute Inc). The study was considered exempt by the University of Rochester institutional review board because it did not involve human subjects, according to federal regulations (IRB #00051935).
RESULTS
Of the 17,255 patients with stage II or III rectal cancer, 6,629 (38%) included in this study had an nCRTesurgery interval time greater than 8 weeks. Table 1 presents bivariate associations between covariates and the 3 nCRTesurgery interval time exposure groups. The mean nCRTesurgery interval time was 56.8 days. The proportion of pCR was 13.2% for those with an Tables 2 and 3 show bivariate associations between pCR and patient characteristics and tumor/treatment characteristics, respectively. The proportion of patients experiencing pCR was then assessed by week after completion of neoadjuvant therapy and plotted against the cumulative proportion of pCR by week, as seen in Figure 2 . The cumulative pCR rate appeared to peak between 10 and 11 weeks (Fig. 2) . Table 4 presents results from the multivariable logistic regression analyses. An nCRTesurgery interval time > 8 weeks was associated with 12% higher odds of pCR as compared with an interval time of 6 to 8 weeks (odds ratio [OR] 1.12, 95% CI 1.01 to 1.25 ). An interval time of < 6 weeks was associated with lower odds of pCR (OR 0.77, 95% CI 0.66 to 0.89). Patients with no insurance (OR 0.60, 95% CI 0.44 to 0.80) and Medicare (OR 0.67, 95% CI 0.52 to 0.85) had a lower odds of pCR. It is interesting to note that the odds of pCR increased over time. Furthermore, increasing tumor size was associated with higher odds of pCR. In addition, high volume hospitals had a higher odds of pCR (OR 1.42, 95% CI 1.12 to 1.80). In the comparison of weekly interval groups, results indicated that the optimal time window was 10 to 11 weeks, as compared to 6 to 8 weeks (OR 1.27, 95% CI 1.01 to 1.60).
Longer nCRTesurgery interval time was not associated with odds of 30-day mortality (OR 1.13, 95% CI 0.76 to 1.69) or tumor regression grade (OR 1.02, 95% CI 0.95 to 1.18), but was associated with higher odds of tumor downstaging (OR 1.11, 95% CI 1.02 to 1.25) and lower odds of unplanned 30-day readmission (OR 0.82, 95% CI 0.70 to 0.92).
DISCUSSION
It is well established that neoadjuvant therapy should be deployed in appropriate patients with locally advanced rectal cancer. In the midst of significant practice variation in the timing between neoadjuvant radiotherapy and surgery, the 1999 Lyon R90-01 trial compared a 2-week vs a 6-week radiotherapyesurgery interval. This trial demonstrated improved clinical tumor response (72% vs 53%) and more frequent histologic tumor regression (26% vs 10%), effectively establishing 6 weeks as the standard RTesurgery interval. 7 However, recent literature has suggested a link between longer nCRTesurgery duration and increased proportion of patients experiencing pCR, but subsequent conclusions regarding the optimal length of time between nCRT completion and surgery have varied. 11 Kalady and colleagues 15 found that an interval ! 8 weeks between neoadjuvant treatment completion and surgical resection was associated with a higher rate of pCR. Additionally, this was correlated with decreased local recurrence and better overall survival. 15 Sloothaak and coworkers 16 showed that surgical resection 15 to 16 weeks after the start of neoadjuvant radiation (approximately 10 weeks after completion) was independently associated with a higher rate of pCR (18%). In contrast, although some studies have reported an increase in pCR with a longer nCRTesurgery interval, others have reported no effect of an increased interval on pCR. 17 In this study, several patient factors were associated with differences in pCR. Patients with Medicaid and no insurance coverage were noted to have a lower rate of pCR than patients with private insurance. This finding may indicate that patients with private health insurance receive more optimal care with fewer treatment interruptions, but this apparent disparity merits further inquiry because, for example, it may simply represent a surrogate marker for superior health performance status. 18, 19 Although our analysis controlled for comorbidity index and clinical stage, one should not be too quick to draw direct conclusions from this finding given the observational nature of the data. Also, an increased odds of pCR was observed over time. However, this may be driven largely by a more recent willingness of providers to recommend a longer nCRTesurgery interval; 46% of patients had an nCRTesurgery interval of >8 weeks in 2011 compared with just 29% of patients in 2006.
Perhaps not surprisingly, increased hospital volume of rectal cancer resections was associated with an independent increase in pCR. This association was similar in strength to that of an nCRTesurgery interval >8 weeks. To our knowledge, this is the first time such an effect has been described in relation to pCR. This result suggests that there may be a comprehensive effect from an institution in which various members of the treatment team such as surgery, medical and radiation oncology, nursing, and other providers are familiar with the work-up and treatment of this disease process. This finding may further support the implementation of a national accreditation program for the perioperative management of patients with rectal cancer.
This study examined the relationship between a longer interval from neoadjuvant radiation to surgical resection and pCR in patients with clinical stage II and III rectal cancer. The overall proportion of patients with pCR was 11.5%, which is on the lower end of the range of 11 It is not surprising to find lower unadjusted rates of pCR in this cohort because it is composed of patients with tumors or various histologic subtypes that have undergone neoadjuvant therapy regimens that may be incomplete. This wide range of reported rates is likely reflective of heterogeneous patient populations receiving different treatment regimens including varying times between neoadjuvant therapy and surgical resection.
This study shows that patients with an nCRTesurgery interval >8 weeks had a small but real increase in the odds of pCR compared with those with an interval between 6 and 8 weeks. To further explore this association, the effect of the nCRTesurgery interval by week was examined. When examining the cumulative proportion of pCR by week, a consistent increase in pCR between 4 and 11 weeks was seen, followed by a leveling off around 10 to 11 weeks. This finding was in accordance with the work of Kalady and associates. 15 In addition, patients who had an nCRTesurgery time of 6 to 8 weeks were compared with each subsequent week in order to determine if there was an optimal waiting period. These results showed that patients who had an nCRTesurgery interval of 10 to 11 weeks had 27% greater odds of pCR than those with an interval of 6 to 8 weeks, which was consistent with the unadjusted results.
However, one must recognize that the histologic response of a tumor to neoadjuvant radiation is not all or nothing, but rather, it exists along a continuum from no response to pCR, although it is typically measured as a categorical measure. This study also found an increased number of patients with tumor downstaging in the longer interval group. This finding is potentially important for both short-term and long-term oncologic outcomes. Obviously, tumor downstaging increases the chances of an R0 resection. In addition, tumor response, as measured by tumor regression grade and downstaging, has also been shown to increase overall and recurrence-free survival in locally advanced rectal cancer. [20] [21] [22] [23] [24] However, despite the results of these previous studies, one should acknowledge the imprecision of clinical T and N staging and as a result, tumor downstaging should not be weighted as strongly as our other outcomes.
It is important to acknowledge the limitations of this study. First, we have limited data about the exact treatment regimen of individual patients, such as specific chemotherapy agents, dose reductions, treatment breaks, or incomplete regimens. Additionally, we have limited information about surgical complications and no long-term mortality information. Also, other factors, such as intolerance to neoadjuvant therapy or resulting treatment toxicity, could result in truncated treatment and potentially decreased pCR. Furthermore, we have no data on whether patients underwent reassessment at 6 to 8 weeks after completion of neoadjuvant therapy, which may have influenced the decision to increase the treatment interval. The higher proportion of patients with pCR in the >8 week group may be, at least in part, because of this. Because we do not know the reason for surgeon decision-making regarding longer intervals, some selection bias may be affecting the results. It is now the practice of some surgeons to extend the interval to surgery if the patient exhibits endoscopic and/or radiologic evidence of a tumor response. Some centers are using PET/CT as an additional tool for interval assessment of tumor response. 25 Such a policy of interval assessment may allow for the identification of patients who have demonstrated a mucosal response to neoadjuvant therapy based on endoscopy supplemented by radiologic reassessment. Clearly, such patients are manifesting a good response to neoadjuvant therapy and could be allocated to a treatment path that involves a longer time period after neoadjuvant therapy to maximize tumor response. Ultimately, some of these patients may meet the criteria for a complete clinical response that at least allows the opportunity to consider an organ preservation strategy (so-called watch and wait strategy). 26 Conversely, patients who do not manifest any significant endoscopic or radiologic response on interval assessment at 6 to 8 weeks after completion of neoadjuvant therapy are not going to benefit from a longer duration post completion and should be scheduled for surgical resection. Such a policy recognizes the heterogeneity in treatment response among patients after neoadjuvant therapy, allowing responders to maximize the benefit from treatment while routing patients who have not responded to resection, as they will not benefit from a longer time interval.
When interpreting the encouraging data from this study, one must acknowledge that only a randomized trial can definitively answer whether a longer interval post neoadjuvant therapy results in improved tumor response and ultimately, complete response. In addition, such a study will allow for a more thorough assessment of the safety of patients with extended intervals. A few trials pursuing this aim are currently accruing patients. [27] [28] [29] [30] However, it appears that clinical practice already appears to be shifting toward a longer duration to surgery, especially in high volume centers. This is of particular interest when considering the emerging role of nonoperative observational strategies currently being offered to select patients with complete clinical response and the randomized trial currently investigating the role of this strategy. 31 However, the issue of local recurrence is intimately tied to an observational strategy. Habr-Gama and coworkers 32 recently reported that local recurrence can occur in up to 31% of patients with initial complete clinical response, but salvage therapy is possible in !90% of recurrences. The patients in that study ultimately had 94% disease control and 78% organ preservation. Model also controlled for age, race, average income and education by ZIP code, hospital type, and hospital location. nCRT, neoadjuvant chemoradiotherapy; OR, odds ratio; RT, radiotherapy.
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